網頁

Tuesday, November 30, 2021

2021 CABA Annual Conference 12/4

2021 CABA Annual Conference


2021 CABA Annual Conference

New Era, New Horizon - Explore with Industry Pioneers and Leaders on the New Frontiers in Healthcare Innovation


Date: Dec 4, 2021

Time: 8:45 am - 12:15 pm EST

Agenda and Speaker Profile

This year’s annual conference of CABA will host a collection of industry pioneers and leaders from a diverse background in science and business. These speakers will share exciting stories and developments and offer their insights in fields that will continue to improve human health, including RNA therapeutics, cell therapies, gene editing, and new materials and methods in life sciences. We hope you will join us and explore the new frontiers in healthcare innovation.

 Image

9:00-9:25

Bo Ying, PhD

Founder and CEO, Abogen Biosciences

CABA President (2018-2019)

Bo Ying, Ph.D., is the founder and CEO of Suzhou Abogen Biosciences, dedicated to mRNA-based therapeutics with focus on immune-oncology as well as infectious diseases. Dr. Ying has decades of experiences in drug development, and he is also an expert in drug delivery system such as lipid nanoparticles. He has successfully led team in the process of drug product development, CMC, tech transfer and IND application for a variety of nucleic acid-based therapeutics. As with the ongoing Covid-19 pandemic, Abogen has developed an mRNA-based vaccine and received IND approval from National Center for Drug Evaluation in China. Currently the vaccine product is under phase III clinical trial. Prior to founding Abogen, Dr. Ying has worked as group leader with proven track record of success at different biotech companies in Boston such as Dicerna Pharmaceuticals, Moderna

Therapeutics and Trucode Gene Repair. Dr. Ying received his bachelor and master’s degrees from Fudan University and a Ph.D. degree from Northeastern University in Boston, USA.


 Image

9:25-9:50

Ke Xu, PhD

Founder, Chairman and CEO of VesiCURE

Extracellular Vesicles (EVs) for Drug Development and Delivery

Dr. Ke Xu is the founding CEO of VesiCURE Therapeutics. Dr. Xu received his Ph.D. in Genetics and Development from the University of Texas Southwestern Medical Center at Dallas. After that, he moved to Harvard University for his postdoc training with Drs. Andy McMahon and Doug Melton. In 2014, Dr. Xu joined Biogen to help set up neurodegenerative models using human iPSC and genome editing technologies. From 2016 and before VesiCURE, he worked at Codiak BioSciences, the first exosome therapeutic company in North America, focusing on discovery research and pipeline development.


 Image

9:50-10:15

Shi-Jiang (John) Lu, PhD, MPH

President and CEO of HebeCell Corporation

CAR NK Cells from 3D-iPSC Bioreactor: One Platform Endless Pipelines

Shi-Jiang (John) Lu, PhD, MPH, is the President and CEO of HebeCell Corporation, focusing on the development and clinical translation of regenerative medicine and cell therapy technologies, especially iPS-CAR-NK cells for the treatment of cancer, autoimmune and viral infectious diseases. Before establishing HebeCell, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which was acquired by Astellas Pharma in 2016. Dr. Lu is an expert in stem cell biology and regenerative medicine with 20 years of experiences. He has been conducting translational researches and discovery of novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. He also has extensive experience in process development and large-scale production of human PSC derivatives under defined conditions for clinical trials. Dr. Lu is the inventor of more than 20 patents in stem cell field: in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, his patent application and citation ranked No. 7 and No. 5, respectively. In addition to stem cell research, Dr. Lu also has more than 10 year experiences in cancer research. Dr. Lu received his BS degree in Biochemistry from Wuhan University, MSc degree in Oncology/Pathophysiology from Peking Union Medical College, MPH degree in Molecular Toxicology/Environmental Sciences from Columbia University and PhD degree in Molecular Cancer Biology from the University of Toronto.

Therapeutics and Trucode Gene Repair. Dr. Ying received his bachelor and master’s degrees from Fudan University and a Ph.D. degree from Northeastern University in Boston, USA.


 Image

10:25-10:50

Ed Zhang, MBA

Co-founder and Interim CEO of Overland Pharmaceuticals, Venture Partner of Hillhouse Capital


Opportunities and Challenges for a Cross-border Cell Therapy NewCo.

Ed Zhang, MBA, serves as Co-founder and Interim CEO at Overland Pharmaceuticals, and is Venture Partner at Hillhouse Capital. Prior to Overland, Mr. Zhang was VP of Corporate Development at Boston Pharmaceuticals, representing a new biotech business model focused on translational clinical development. As part of its founding team, Mr. Zhang led corporate development and strategic initiatives including establishing partnerships with leading global pharma and biotech companies. Before joining Boston Pharma, Mr. Zhang headed Global Business Development for Sanofi’s Renal Strategic Unit, and was Director of Commercial Operations and Strategic Development at Genzyme before its acquisition by Sanofi. Mr. Zhang started his career as a medicinal chemist at Pharmacia & Upjohn and now brings over 18 years of biopharma industrial experience to Overland. Mr. Zhang holds an MBA from Kellogg School of Management at Northwestern University, an MS in chemistry from Binghamton University, and a BS from Nanjing University.


 Image

10:50-11:15

Eric von Hofe, PhD

President and COO of AffyImmune Therapeutics


Affinity Tune and Track CAR T Cell Technology for Solid Tumors

Eric von Hofe, Ph.D., has over 25 years of experience in biotechnology with a focus on cancer immunotherapy and technology development. Before joining AffyImmune Therapeutics, he led development efforts at Antigen Express advancing the clinical development of novel cancer immunotherapies. Prior to that he held positions of increasing responsibility at Millennium Pharmaceuticals aligning novel technology initiatives with genomics-based drug development objectives.


 Image

11:25-11:50

Tasuku Kitada, PhD

President and Head of R&D of Strand Therapeutics


Progamming mRNA for Cancer Immunotherapy

Dr. Tasuku Kitada is President and Head of R&D of Strand Therapeutics. He co-founded Strand and serves on its Board of Directors. Prior to Strand, Dr. Kitada was Senior Biotechnology Analyst at Candriam Investors Group, where he conducted due diligence for the company’s multi-billion-dollar biopharma public equity investment strategy. At Candriam, he focused on cell and gene therapy companies, and also covered numerous oncology companies. Currently, Dr. Kitada continues to serve Candriam Investors Group as an advisor. Prior to Candriam, Dr. Kitada was a researcher at the Synthetic Biology Center at MIT, where he became the first scientist to create synthetic gene circuits using synthetic mRNA. This was the first demonstration of post-transcriptional circuits that can be “wired” to create a variety of networks of increasing complexity, which enabled cell type specific expression as well as small-molecule based control of gene expression from synthetic mRNA. This important research led to publications in Science, Nature Biotechnology, and Nature Chemical Biology. The mRNA synthetic biology platform developed from this research has been exclusively licensed to Strand. Dr. Kitada holds a Ph.D. in Molecular Biology from the University of California, Los Angeles and a B.S. in Biophysics and Biochemistry from the University of Tokyo.


 Image

11:50-12:15

David Lebwohl, PhD

EVP and CMO of Intellia Therapeutics


CRISPR/Cas9 In Vivo Genome Editing for Transthyretin Amyloidosis: First Clinical Results

Dr. David Lebwohl is the Chief Medical Officer at Intellia Therapeutics, a genome editing company. Before Intellia, Dr. Lebwohl was the Chief Medical Officer at Semma Therapeutics Inc., and led drug development teams at Novartis Pharmaceuticals and Bristol Myers Squibb. At Novartis, he was Senior Vice President and Program Head, CAR-T Teams, responsible for the development of the breakthrough

therapy Kymriah® (tisagenlecleucel), approved for leukemia and lymphoma. Under his leadership,

the blockbuster drug Afinitor® (everolimus) was approved for metastatic breast, neuroendocrine, and

kidney cancer as well as the rare genetic disease tuberous sclerosis. Dr. Lebwohl received an AB in

Biochemical Sciences from Harvard College and an MD from Yale University. He completed his

fellowship training at Memorial Sloan Kettering Cancer Center in medical oncology and hematology

and his residency in internal medicine at the Brigham and Women’s Hospital in Boston.



线上会议

Zoom Meeting

12/04/2021

8:45 am - 12:15 pm EST

ID: 87540625701

Passcode: 718858



扫码或点击“阅读原文”

直达会议


CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.


No comments:

Post a Comment